Intimal hyperplasia, the key event of arterial restenosis, is a result of cell proliferation and cell migration. Atorvastatin exerts an inhibitory effect on cell proliferation and migration, but the mechanism remains largely unknown. p16, as a well-known tumor suppressor, was also reported to suppress cell growth and migration, but with an unclear mechanism. In this study, we demonstrated that atorvastatin represses cell proliferation and migration in vascular smooth muscle cells (VSMCs) and that this process is mediated by p16. Furthermore, we found that DNA methylation in the p16 promoter was reduced and p16 expression was restored in VSMCs treated with 5-aza-2 0 -deoxycytidine or atorvastatin. However, the effect was absent when DNA methyltransferase 1 (DNMT1) was knocked down with RNA interference. These observations demonstrated that atorvastatin regulates p16 expression via DNMT1-induced DNA methylation in the p16 promoter. In addition, we found that the mitogen-activated protein kinase (MAPK) pathway was involved in the regulation of p16 by DNMT1, and MAPK inhibitors partially released the effects of atorvastatin on p16 and DNMT1. Finally, we illustrated that atorvastatin inhibits neointima formation and modulates p16 expression in balloon catheter-injured rat carotid artery. Taken together, we demonstrated that atorvastatin inhibits neointima formation through inducing p16 expression by affecting DNA methylation in the p16 promoter region.
Intimal hyperplasia, the key event of arterial restenosis, is a result of cell proliferation and cell migration. Atorvastatin exerts an inhibitory effect on cell proliferation and migration, but the mechanism remains largely unknown. p16, as a well-known tumor suppressor, was also reported to suppress cell growth and migration, but with an unclear mechanism. In this study, we demonstrated that atorvastatin represses cell proliferation and migration in vascular smooth muscle cells (VSMCs) and that this process is mediated by p16. Furthermore, we found that DNA methylation in the p16 promoter was reduced and p16 expression was restored in VSMCs treated with 5-aza-2 0 -deoxycytidine or atorvastatin. However, the effect was absent when DNA methyltransferase 1 (DNMT1) was knocked down with RNA interference. These observations demonstrated that atorvastatin regulates p16 expression via DNMT1-induced DNA methylation in the p16 promoter. In addition, we found that the mitogen-activated protein kinase (MAPK) pathway was involved in the regulation of p16 by DNMT1, and MAPK inhibitors partially released the effects of atorvastatin on p16 and DNMT1. Finally, we illustrated that atorvastatin inhibits neointima formation and modulates p16 expression in balloon catheter-injured rat carotid artery. Taken together, we demonstrated that atorvastatin inhibits neointima formation through inducing p16 expression by affecting DNA methylation in the p16 promoter region.
Introduction
Arterial restenosis is a common adverse event following interventional or surgical treatment of arterial diseases, and its major cause is intimal hyperplasia [1, 2] . Several reports document that the proliferation and migration of vascular smooth muscle cells (VSMCs) is the key mechanism of intimal hyperplasia, and inhibition of the proliferation and migration of VSMCs might be an optimal solution for the treatment of arterial restenosis [3] [4] [5] [6] [7] .
Statins, a class of hydroxymethylglutaryl coenzyme A reductase inhibitors, have been reported to have both anti-inflammatory and antiproliferative properties and are widely used as cholesterol-lowering agents [8, 9] . Atorvastatin is widely used for coronary artery disease patients during index hospitalization. Recent studies have reported that it inhibits cell proliferation, represses cell migration, and induces cell apoptosis [10] [11] [12] . Previous studies demonstrated that atorvastatin exerted an arterial healing effect on the restenosis process, elevated cell senescence and apoptosis, and promoted p16 expression [13] [14] [15] . However, the mechanism of atorvastatin's effect in these cell processes remains largely unclear.
The tumor suppressor gene p16, also known as p16 INK4a and CDKN2A, encodes a 148 amino acid protein that exerts a key role in the G1 phase of the cell cycle as a cyclin-dependent kinase inhibitor [16, 17] . As a tumor suppressor gene, p16 affects cell progression and tumorigenesis through inhibiting cell proliferation and migration and inducing apoptosis [18] [19] [20] . Several reports demonstrated reduced expression of p16 in many malignant tumors and the level of p16 was a predictor for survival following chemotherapeutic intervention in melanoma, osteosarcoma, pleural mesothelioma, and kidney, bladder, pancreatic, brain, colon, cervical, and non-small-cell lung cancers [17, 18, [21] [22] [23] [24] . Recent reports revealed that overexpressed p16 could alleviate angioplastyinduced intimal hyperplasia in the coronary artery and accelerate the development of age-related cardiovascular diseases [25, 26] . It has been reported that p16 expression was regulated by the DNA methylation of CpGs in its promoter, which reduced its expression [27, 28] .
DNA methylation happens predominantly at position 5 of cytosines of CpG dinucleotides throughout the genome and is catalyzed by DNA methyltransferases (DNMTs). In mammals, there are three different DNMTs: DNMT1 is the major maintenance methyltransferase during DNA replication using hemimethylated DNA; DNMT3A and DNMT3B are the de novo methyltransferases [29, 30] . DNA methylation plays important roles in gene expression and influences many biological and cellular processes, such as DNA repair, genomic imprinting, cell growth, cell differentiation, cell proliferation, and tumorigenesis [31] [32] [33] . Knockdown of DNMT1 led to the repression of cell proliferation and migration and induction of apoptosis [34, 35] . Previous research illustrated that DNA methylation in the CpG islands of suppressor of cytokine signaling 3 (SOCS3) induced by DNMT1 could exert influence on smooth muscle cell proliferation involved in intimal hyperplasia and restenosis [36, 37] .
The mitogen-activated protein kinases (MAPKs), a family of serine/threonine kinases, phosphorylate their own dual serine and threonine residues or those of their specific substrates in a signaling cascade [38] [39] [40] . Activated MAPKs translocate to the cell nucleus and regulate gene expression, cell proliferation, cell migration, apoptosis, and mitosis, as well as maintaining homeostasis [41] [42] [43] [44] . There are three major MAPK family members: c-Jun N-terminal kinase (JNK) and p38-MAPK, which are activated in response to cellular and environmental stresses, and extracellular signalregulated kinase (ERK), which is activated in response to growth stimuli [45, 46] . Recent studies reported that the activation of MAPKs could modulate cell proliferation and cell migration in VSMCs and influence the intimal hyperplasia in a carotid injury model [47] [48] [49] . There is controversy regarding regulation of DNMT1 expression by MAPKs as some researchers showed that activated JNK inhibited DNMT1 expression and others that phosphorylated JNK and ERK induced the expression of DNMT1 [50, 51] . Lu and colleagues found that the inhibition of ERK-MAPK could regulate p16 expression via changing DNA methylation of the p16 promoter by down-regulating DNMT1 expression [52] .
In this study, we dissected the mechanism of atorvastatin in VSMCs. First, we demonstrated inhibitory function of atorvastatin on cell proliferation and migration of VSMCs through the modulation of p16 expression. Further, we demonstrated that the regulation of p16 expression by atorvastatin was mediated by DNMT1 through modulating DNA methylation in the p16 promoter. In addition, we found that the MAPK pathway was involved in the regulation of p16 by DNMT1. Finally, we demonstrated that atorvastatin inhibits neointima formation and modulates p16 expression in balloon catheter-injured rat carotid artery.
Results

Atorvastatin inhibits cell growth and migration and induces apoptosis in VSMCs
Previous studies reported that statins could influence cell proliferation and cell migration. In order to determine the effect of atorvastatin on rat VSMCs, we employed a Cell Counting Kit-8 (CCK8) assay, western blot, and a Transwell cell migration assay to analyze the cells treated with atorvastatin for 24 h in different concentrations, namely 0, 0.5, 1, and 2 lM. The CCK8 assay showed that the growth of VSMCs was inhibited by atorvastatin in a dose-dependent manner (Fig. 1A) . Furthermore, western blot results showed that the expression of p53, an apoptotic biomarker, was elevated by atorvastatin, indicating that atorvastatin may induce apoptosis of VSMCs (Fig. 1B ). An annexin V-propidium iodide (PI) assay demonstrated that atorvastatin could increase apoptosis of VSMCs in a concentration-dependent manner (Fig. 1C) . In addition, the results of a cell migration assay illustrated that atorvastatin inhibited VSMC migration compared with control cells treated with DMSO (Fig. 1D) . Taken together, these results demonstrated that atorvastatin inhibited proliferation and migration and induced apoptosis of rat VSMCs.
Atorvastatin represses cell proliferation and migration by modulating p16 expression
Previous studies have shown that p16 suppresses cell proliferation and migration. We proposed that p16 Each experiment was repeated a minimum of three times, and statistically significant differences are indicated by asterisks: *P < 0.05, **P < 0.01; two-tailed Student's t-test.
might be involved in atorvastatin-induced inhibition of cell proliferation and migration. To test our hypothesis, we employed western blot and quantitative real-time polymerase chain reaction (q-PCR) to detect the expression of p16 in cells treated with atorvastatin. q-PCR analysis showed an elevated level of p16 mRNA transcripts in a dose-dependent manner when cells were treated with atorvastatin ( Fig. 2A,C) . Western blot results further illustrated that atorvastatin promoted p16 expression (Fig. 2B,D) . These results proved that p16 expression was regulated by atorvastatin.
To elucidate the potential function of p16 in VSMCs treated with atorvastatin, we designed three short-hairpin RNAs (shp16 RNA) specific to rat p16. q-PCR assay demonstrated that all three shp16 RNAs could reduce p16 expression (Fig. 2E) . Interestingly, we found that when p16 was knocked down, the inhibitory effect of atorvastatin on VSMC viability and migration was partially released in CCK8 and cell migration assays (Fig. 2F,G) .
Taken together, these results demonstrated that atorvastatin inhibits cell proliferation and migration through regulating p16 expression.
p16 expression was regulated by atorvastatin through modulating the methylation status in the p16 promoter Previous work reported that p16 expression could be regulated by DNA methylation. We wondered whether p16 expression was regulated through the modulation of DNA methylation in VSMCs. We treated VSMCs with the DNA methylation inhibitor 5-aza-2 0 -deoxycytidine (AZA). The results of western blot showed that DNMT1 expression was repressed by AZA, but no significant difference was observed in DNMT3A and DNMT3B expression (Fig. 3A) . Furthermore, the results of q-PCR analysis illustrated that p16 mRNA transcripts were restored by AZA ( Fig. 3B ) and western blot showed an elevated p16 expression after AZA treatment (Fig. 3C ). These results indicated that p16 expression could be regulated by DNA methylation. To further confirm the hypothesis, we employed the sodium bisulfite DNA sequencing assay to examine the methylation status of CpGs in the upstream p16 promoter region in VSMCs treated with AZA or PBS. As expected, VSMCs treated with AZA showed a reduced level of CpG methylation (10.9%) compared with control cells (20.0%) in the p16 promoter region (Fig. 3D) . These results demonstrated that p16 expression could be modulated by the CpG methylation status of the p16 promoter in VSMCs.
p16 expression was regulated by DNMT1
Given that AZA is a DNMT1 inhibitor and regulates p16 expression, we proposed that DNMT1 might regulate atorvastatin-induced modulation of p16 expression. Therefore, we detected the expression of DNMTs in VSMCs treated with atorvastatin and found that atorvastatin could repress DNMT1 expression, without altering expression of DNMT3A or DNMTT3B (Fig. 4A) . Furthermore, sodium bisulfite DNA sequencing showed that atorvastatin reduced the level of CpG methylation (7.3%) significantly compared with that in control cells (20.0%) in the p16 promoter region (Fig. 3D ). All these data indicated that atorvastatin inhibited DNMT1 expression, and subsequently induced p16 expression through regulating DNA methylation in the p16 promoter.
To further confirm this, we overexpressed DNMT1 in VSMCs (Fig. 4B ,C) and found that overexpressed DNMT1 inhibited p16 expression (Fig. 4D,E) , while the expression of p16 was elevated (Fig. 4G ,H) when DNMT1 was knocked down with shRNA (Fig. 4F ). In addition, we added atorvastatin (1 lM) to VSMCs inhibited with shDNMT1 or overexpressed DNMT1 for approximately 24 h and detected the p16 expression. We found that the repression of DNMT1 could alleviate the atorvastatin-induced p16 expression and overexpressed DNMT1 enhanced it. These results provide a direct link between atorvastatin treatment and p16 expression through the regulation of DNMT1 (Fig. 4I) . Therefore, these data demonstrated that p16 expression was regulated by DNMT1 in VSMCs treated with atorvastatin.
Taken together, our study found that p16 expression was regulated by DNMT1 by affecting the DNA methylation in the promoter region of p16 in VSMCs treated with atorvastatin.
The MAPK pathway is involved in DNMT1/p16 regulation in VSMCs treated with atorvastatin Previous studies documented that MAPKs could modulate cell proliferation and migration, and so we wondered whether MAPKs are involved in the atorvastatin-induced inhibition of cell proliferation and migration. We employed western blot to detect the protein levels of the three well-characterized MAPK subfamilies, JNK, p38, and ERK, as well as their phosphorylated forms in VSMCs treated with atorvastatin at different concentrations, namely 0, 0.5, and 1 lM, for 24 h. The results illustrated an increased protein level of p-JNK, p-p38, and p-ERK, but without alteration in JNK, p38, and ERK, in VSMCs treated with atorvastatin (Fig. 5A) . These results demonstrated atorvastatin induced the activation of the three subfamilies of MAPKs.
Given that atorvastatin could affect DNMT1/p16 expression and influenced the activation of MAPKs, we then examined the function of MAPKs in DNMT1/p16 expression in VSMCs treated with The P values were 0.0022 for short hairpin negative control (shNC) and atorvastatin, and 0.037 for shp16 and atorvastatin. (G) Cell migration assay of VSMCs treated with atorvastatin together with shp16. The P values were 0.0049 for shNC and atorvastatin, and 0.042 for shP16 and atorvastatin. Each experiment was repeated a minimum of three times and statistically significant differences are indicated by asterisks: *P < 0.05, **P < 0.01; two-tailed Student's t-test.
atorvastatin. We treated the cells with atorvastatin alone or coupled with p-JNK inhibitor SP100625, pp38 inhibitor SB203580, or p-ERK inhibitor AZD6244. The western blot results demonstrated that the activation of JNK, p38, and ERK was repressed by their corresponding inhibitor (Fig. 5B-D) . Of note, we found the inhibitors of MAPKs could restore the atorvastatin-induced DNMT1 down-regulation and p16 elevation (Fig. 5B-D) . These results illustrated that the MAPK pathway is involved in the regulation of atorvastatin-induced modulation of DNMT1 and p16 expression.
As both atorvastatin and MAPKs could affect cell proliferation and metastasis, we employed the CCK8 assay and cell migration assay to test the influence of the MAPK inhibitors on VSMCs. The results of the CCK8 assay showed a restoration of cell proliferation in cells treated with atorvastatin and MAPK inhibitors together (Fig. 6A) , compared with these cells treated with atorvastatin alone. The cell migration assay demonstrated that the MAPK inhibitors rescued the inhibition induced by atorvastatin (Fig. 6B) .
Taken together, our research suggested that the MAPK pathway affected atorvastatin-induced inhibition of cell proliferation and migration via modulating DNMT1/p16 expression in VSMCs.
Atorvastatin inhibits neointima formation and promotes p16 expression in vivo
Research suggested that inhibition of the proliferation and migration of VSMCs was a way to alleviate artery restenosis. We have already illustrated that atorvastatin could inhibit cell proliferation and migration by modulation of the expression profile of MAPKs/ DNMT1/p16. These results provide the basis for clinical application of atorvastatin in the interventional or surgical treatment of arterial diseases. Thus, we used GAPDH and b-actin expression were measured as control, and each experiment was repeated a minimum of three times. Statistically significant differences are indicated by asterisks: *P < 0.05, **P < 0.01; two-tailed Student's t test.
balloon catheter-injured rat carotid artery to determine the function of atorvastatin in vivo. Hematoxylin-eosin staining demonstrated that atorvastatin rescued cell proliferation and intimal hyperplasia (Fig. 7A) . We further detected the expression of p16 in this model. The results of q-PCR and western blot illustrated that both the mRNA transcripts and protein level were restored in samples treated with atorvastatin (Fig. 7B,  C) . Taken together, these results demonstrated that atorvastatin exhibits an inhibitory effect on cell proliferation in vivo and may be an effective agent for prevention of restenosis after angioplasty.
Discussion
The role of DNA methylation in gene regulation has been widely reported. In this study, we investigated the regulation of p16 expression by DNA methylation and shDNMT1. b-Actin expression were measured as control, and each experiment was repeated a minimum of three times. Statistically significant differences are indicated by asterisks: *P < 0.05, **P < 0.01; two-tailed Student's t-test.
its influence in the atorvastatin-induced inhibitory effect in VSMCs. We tested the inhibitory function of atorvastatin on cell proliferation and migration of VSMCs. Further, we illustrated the elevated level of p16 in VSMCs treated with atorvastatin and its mechanism. Finally, we dissected the function of the MAPK pathway in the regulation of p16 by DNMT1 and the influence on cell growth and migration. Previous studies documented that the inhibition of cell proliferation and migration was an effective way to alleviate intimal hyperplasia following interventional or surgical treatment of arterial diseases. We identified the inhibitory effects of atorvastatin in cell proliferation and migration (Fig. 1) . We proposed that atorvastatin could be applied in the clinical treatment of intimal hyperplasia. The results from the balloon catheter-injured rat carotid artery demonstrated that atorvastatin eased the intimal hyperplasia (Fig. 7A) . These results supply the basis for the application of atorvastatin in interventional or surgical treatment of arterial diseases.
The MAPK pathway is involved in cell progress, such as cell growth, cell proliferation, the cell cycle, metastasis, and apoptosis. However, the function of MAPKs in cell metastasis and growth is perplexing as it is controversial in different cell types and in different laboratories [42]. In our study, we found that JNK, ERK, and p38 were activated in atorvastatin-induced inhibition of cell proliferation and metastasis (Fig. 5A) . Thus, we sought to dissect the mechanism of MAPKs in VSMCs treated with atorvastatin. Previous work documenting the role of MAPKs in modulating DNMT1 expression is also controversial [53] . Thus, we employed inhibitors of MAPKs in VSMCs treated with atorvastatin and found that all the three inhibitors could alleviate the influence of atorvastatin on VSMCs (Fig. 5B-D) . These results The P values were 0.006143 for atorvastatin, 0.0027 for Ator+SD100625, 0.043 for Ator+SB203580, and 0.047 for Ator+AZD6244. Each experiment was repeated a minimum of three times, and statistically significant differences are indicated by asterisks: *P < 0.05, **P < 0.01; two-tailed Student's t-test.
demonstrated that MAPKs exerted a regulatory function in VSMCs via regulating DNMT1 expression. However, more work is still needed to elucidate the real function and mechanism of both MAPKs and DNMT1 in cell proliferation and metastasis.
The biomarkers specific for disease facilitate diagnosis, treatment, and prognosis, and so searching for characteristic biomarkers specific for diseases is an urgent task for scientists and clinicians. p16, as a tumor suppresser gene, was reported to affect cell proliferation and migration. In this study, we found that p16 expression was regulated by atorvastatin-induced modulation of DNA methylation in the p16 promoter. Furthermore, our study illustrated that p16 expression was rescued by atorvastatin in balloon catheter-injured rat carotid artery (Fig. 7B,C) . This indicated that p16 expression might be a potential biomarker for the assessment of risk of restenosis after angioplasty, as well as serving as a novel therapeutic target.
Taken together, we demonstrated that atorvastatin suppresses VSMC proliferation and cell migration through inhibiting DNMT1 expression, and subsequently promoting p16 expression, during which process the MAPK pathway is also involved. In addition, we proved that atorvastatin inhibits neointima formation and modulates p16 expression in balloon catheterinjured rat carotid artery. The P values were 0.0023 for injury and 0.011 for injury and atorvastatin. Statistically significant differences are indicated by asterisks: *P < 0.05, **P < 0.01; two-tailed Student's t-test. The sections of rat carotid arteries were prepared on day 14 after balloon injury.
Materials and methods
Animals and ethics statement
Rat carotid balloon injury of the left common carotid artery of male Sprague-Dawley rats was performed as described [54] . In brief, Sprague-Dawley rats (male, 250-300 g) were anesthetized by intraperitoneal injection of chloral hydrate (350 mgÁkg À1 , i.p.). The balloon was introduced through the left common and external carotid arteries and the inflated balloon withdrawn three times. Then, the catheter was removed, the external carotid artery was ligated, and the common carotid artery was restored. For preparing a sham operation control, rats were operation on as described above except for the balloon injury.
Plasmid construction
The p16 expression constructs were based on the lentivirus vector pLVX-puro-EGFP. The DNA fragment of p16 was amplified from the cDNA of HEK293 by PCR using the primers as follows: forward primer: 5 0 -CCGGAATT CATGGGTCGCAGGTTCTTGG-3 0 , and reverse primer:
It was ligated into pLVX-puro-EGFP vector at EcoRI and BamHI sites. Amplification conditions were as follows. First, samples were denatured at 94°C for 5 min, followed by 28 cycles of 94°C for 20 s, 58°C for 20 s and 68°C for 30 s, and an extension of 10 min at 72°C. Specific short-hairpin RNAs (shRNAs) against p16 and control shRNA were designed and synthesized by GenePharma (Shanghai, China). shRNAs were ligated into the AgeI/EcoRI sites in lentivirus vector pLKO.1. shP16, sense: 5 0 -GGTTCTTGGTCACTGTGAGGA-3 0 ; ShDNMT1, sense:
Cell culture, lentivirus production, and cell infection
Rat VSMCs and 293T cells were cultured in Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA, USA), supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin in a humidified atmosphere at 37°C containing 5% CO 2 . Lentivirus package and transfection were performed as described as follow. The shuttle vectors and helper plasmids were transfected into the 293T cells using Lipofectamine-2000 (Invitrogen) in Opti-MEM culture medium according to the manufacturer's instructions. The virus was harvested 72 h after transfection and transfected the rat VSMCs for about 72 h.
Sodium bisulfite DNA sequencing assay
Rat VSMCs were treated with 5-aza-2 0 -deoxycytidine , and GAPDH was used as control.
Western blot assay
Total protein was extracted using RIPA (ShineGene Molecular Biotech, Inc., Shanghai, China) and the concentration was measured using a BCA Protein Assay Kit (Pierce Chemical Co, Rockford, IL, USA). Western blot analysis was performed as described previously [55] .
The following primary antibodies were used according to the manufacturer's protocol: p16 antibody (ab51243, Abcam, Cambridge, MA, USA), p53 antibody (Abcam, ab1101), DNMT1 antibody (sc-135887, Santa Cruz Biotechnology, Dallas, TX, USA), DNMT3A antibody (Santa Cruz Biotechnology, sc-10234), DNMT3B antibody (Santa Cruz Biotechnology, sc-376043), p-JNK antibody (cst-9255s, Cell Signaling Technology, Danvers, MA, USA), JNK antibody (Cell Signaling Technology, cst-9255s), p-ERK antibody (Cell Signaling Technology, cst-9911), ERK antibody (Cell Signaling Technology, cst-4370s), p-P38 antibody (Cell Signaling Technology, cst-4631), p38 antibody (Cell Signaling Technology, cst-8690). b-Actin antibody (DH0251, Donghuan, Shanghai, China) and GAPDH (Donghuan, DH0261) were used as control. Immunoreactivity was visualized using an ECL western blot system (Donghuan, DH0101).
CCK8 assay
Cells with different treatments were plated in a 96-well plate and the cell proliferation detected with Cell Counting Kit-8 (Beyotime Institute of Biotechnology, Shanghai, China) according to the manufacturer's instructions. Cells were cultured in a 96-well plate, following incubation with atorvastatin at different concentrations, namely 0.5, 1.0, 1.5, and 2.0 lM, at 37°C with air containing 5% CO 2 for about 24 h. Then, CCK8 (Solarbio, Beijing, China) reagent was added and the attenuance was measured at 570 nm and the percentage cell viability was calculated as described previously [56] .
Cell migration assay
The migration potential of rat VSMCs with different treatments was detected using Matrigel Migration Chambers supplied by BD Biosciences (Franklin Lakes, NJ, USA) according to the manufacturer's protocol. The cells were stained with crystal violet and observed under a microscope. The assay was performed as follows: the cells with different treatments were planted into the upper Transwell chamber, while the lower chamber was filled with complete medium containing 10% fetal bovine serum. Cells were incubated for 18 h and stained with crystal violet for 15 min, air-dried, and observed under a microscope.
Rat carotid balloon injury
Balloon denudation of the left common carotid artery of male Sprague-Dawley rats was operated as described previously [57] . Briefly, Sprague-Dawley rats (300-340 g) were anesthetized with chloral hydrate (350 mgÁkg À1 , intraperitoneally). Then, the skin of the neck was sterilized with 75% alcohol, and the left common and external carotid arteries of the rats were isolated and exposed. Then, we introduced a 1.5 F Fogarty catheter (Edwards Lifesciences, Irvine, CA, USA) into the common carotid artery through an arteriotomy in the external carotid artery, inflated it to 2.0-3.0 atm and withdrew it, performing this three times. Then, we ligated the external carotid artery and restored the blood flow. To prepare the shamoperated rats, we exposed and connected the left common carotid artery and the external carotid artery as described above, but the catheter was not inserted into the blood vessel.
Statistical analysis
Data were analyzed using the statistical software SPSS (v. 13.0.0; SPSS Inc., Chicago, IL, USA) and presented as the mean AE standard deviation. All experiments were repeated a minimum of three times. Results were considered statistically significant at *P < 0.05 and highly significant difference at **P < 0.01 in a two-tailed Student's t-test.
